CN100584358C - 一种治疗心脑血管病的中药组合物及其制剂和制备方法 - Google Patents
一种治疗心脑血管病的中药组合物及其制剂和制备方法 Download PDFInfo
- Publication number
- CN100584358C CN100584358C CN200610081138A CN200610081138A CN100584358C CN 100584358 C CN100584358 C CN 100584358C CN 200610081138 A CN200610081138 A CN 200610081138A CN 200610081138 A CN200610081138 A CN 200610081138A CN 100584358 C CN100584358 C CN 100584358C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- cortex moutan
- medicine composition
- total glycosides
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 201000010099 disease Diseases 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 2
- 239000011347 resin Substances 0.000 claims abstract description 34
- 229920005989 resin Polymers 0.000 claims abstract description 34
- 229930182470 glycoside Natural products 0.000 claims description 75
- 150000002338 glycosides Chemical class 0.000 claims description 75
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 239000012567 medical material Substances 0.000 claims description 19
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 18
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 17
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000012535 impurity Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 238000001291 vacuum drying Methods 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000003795 desorption Methods 0.000 claims description 6
- 239000000469 ethanolic extract Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000002481 ethanol extraction Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000003463 adsorbent Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 235000010265 sodium sulphite Nutrition 0.000 claims description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 2
- 239000002689 soil Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 238000005516 engineering process Methods 0.000 abstract description 6
- 240000005001 Paeonia suffruticosa Species 0.000 abstract description 3
- AVIUTYMRHHBXPB-UXXRCYHCSA-N Paeonoside Natural products COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 AVIUTYMRHHBXPB-UXXRCYHCSA-N 0.000 abstract description 3
- AVIUTYMRHHBXPB-UHFFFAOYSA-N glucopaeonol Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(CO)O2)O)=C1 AVIUTYMRHHBXPB-UHFFFAOYSA-N 0.000 abstract description 3
- XFFQVRFGLSBFON-DEFKTLOSSA-N kaempferol 3,7-di-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 XFFQVRFGLSBFON-DEFKTLOSSA-N 0.000 abstract description 3
- 208000019553 vascular disease Diseases 0.000 abstract description 3
- 230000000747 cardiac effect Effects 0.000 abstract 2
- 230000002490 cerebral effect Effects 0.000 abstract 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 26
- 235000019441 ethanol Nutrition 0.000 description 24
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 16
- 206010008118 cerebral infarction Diseases 0.000 description 16
- 208000010125 myocardial infarction Diseases 0.000 description 16
- 241000282472 Canis lupus familiaris Species 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 208000031225 myocardial ischemia Diseases 0.000 description 9
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 8
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 8
- 201000006474 Brain Ischemia Diseases 0.000 description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical group C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- -1 r Species 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 3
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000000269 carotid artery external Anatomy 0.000 description 3
- 210000004004 carotid artery internal Anatomy 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 210000003657 middle cerebral artery Anatomy 0.000 description 3
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 229960000715 nimodipine Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 2
- IRLNKOAURQPXIQ-WWWUCTDISA-N Apiopaeonoside Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@](O)(CO)CO3)O2)cc(OC)cc1 IRLNKOAURQPXIQ-WWWUCTDISA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- IDZZECHGWAZTIB-NYBIBFQCSA-N Paeonolide Chemical compound COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@@H](O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-NYBIBFQCSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical group OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- VIWQCBZFJFSCLC-UXPYWIADSA-N Benzoyloxypaeoniflorin Natural products O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@]23[C@]4(COC(=O)c5ccc(O)cc5)[C@@H]5OC2(C)C[C@@](O)(O5)[C@@H]4C3)O1)c1ccccc1 VIWQCBZFJFSCLC-UXPYWIADSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000009785 Inferior Wall Myocardial Infarction Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- IDZZECHGWAZTIB-WPQJODJHSA-N Paeonolide Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3[C@@H](O)[C@H](O)[C@@H](O)CO3)O2)cc(OC)cc1 IDZZECHGWAZTIB-WPQJODJHSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241001593750 Turcica Species 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- IDZZECHGWAZTIB-UHFFFAOYSA-N affinoside Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- VIWQCBZFJFSCLC-HRCYFWENSA-N beta-benzoyloxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-HRCYFWENSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000009835 oxypaeoniflora Substances 0.000 description 1
- FCHVXNVDFYXLIL-QYDSDWLYSA-N oxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=C(O)C=C1 FCHVXNVDFYXLIL-QYDSDWLYSA-N 0.000 description 1
- RLXWQODPAWIVOI-UHFFFAOYSA-N oxypaeoniflorin Natural products OCC1OC(OC23CC4C5(O)CC2OC(O5)C34COC(=O)c6ccc(O)cc6)C(O)C(O)C1O RLXWQODPAWIVOI-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229930192151 suffruticoside Natural products 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000009595 xiao yao wan Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610081138A CN100584358C (zh) | 2006-05-22 | 2006-05-22 | 一种治疗心脑血管病的中药组合物及其制剂和制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610081138A CN100584358C (zh) | 2006-05-22 | 2006-05-22 | 一种治疗心脑血管病的中药组合物及其制剂和制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101077364A CN101077364A (zh) | 2007-11-28 |
CN100584358C true CN100584358C (zh) | 2010-01-27 |
Family
ID=38905135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200610081138A Expired - Fee Related CN100584358C (zh) | 2006-05-22 | 2006-05-22 | 一种治疗心脑血管病的中药组合物及其制剂和制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100584358C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102283911B (zh) * | 2011-09-16 | 2013-03-13 | 河南省中医药研究院 | 治疗缺血性中风的益气活血风静胶囊 |
CN108451965A (zh) * | 2018-05-03 | 2018-08-28 | 黄山学院 | 一种具有抗心肌缺血作用的赤芍萜苷组合物及其制备方法 |
CN115645464B (zh) * | 2022-11-11 | 2024-04-12 | 广州中医药大学(广州中医药研究院) | 一种治疗动脉粥样硬化和脂肪肝的中药组合物及其应用 |
-
2006
- 2006-05-22 CN CN200610081138A patent/CN100584358C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101077364A (zh) | 2007-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102362881A (zh) | 银杏洋参制剂的生产方法 | |
CN102512482A (zh) | 一种鬼箭羽提取物及其降糖活性与在制备降血糖制品中的应用 | |
CN1706397B (zh) | 具有升高白细胞作用的芍药苷与芍药内酯苷的组合物 | |
CN1919248B (zh) | 一种治疗心脑血管病的中药制剂 | |
CN101164566B (zh) | 一种牡丹叶总苷提取物及其制备方法和用途 | |
CN107412430A (zh) | 一种玄参水提物及其应用 | |
CN102526141B (zh) | 翼首草总环烯醚萜苷提取物及其制备方法和用途 | |
CN100584358C (zh) | 一种治疗心脑血管病的中药组合物及其制剂和制备方法 | |
CN102743374B (zh) | 1,5,8-三羟基-3-甲氧基*酮的制备方法 | |
CN100509009C (zh) | 一种治疗心脑血管病、缺血性中风的中药制剂及其制备方法 | |
CN1931233B (zh) | 一种用于治疗心脑血管疾病的丹参和淫羊藿的药用组合物 | |
CN100509010C (zh) | 一种治疗心脑血管病的中药制剂及其制备方法 | |
CN101850063A (zh) | 一种防治痛风的药物制剂及其制备方法 | |
CN100584345C (zh) | 具抗病毒作用的小紫金牛提取物及其提取方法和应用 | |
CN104707023A (zh) | 一种治疗***的中药组合物及其制备方法 | |
CN104116753B (zh) | 桃叶珊瑚苷在制备治疗特发性肺纤维化药物中的应用 | |
CN1919238B (zh) | 一种治疗心脑血管病的药物 | |
CN1919247B (zh) | 一种治疗心脑血管病的中药 | |
CN103933386B (zh) | 一种用于治疗血友病的复方血友胶囊及其制备方法 | |
CN103239618A (zh) | 一种治疗慢性肝炎、肝硬化的中药组合物及其制备方法 | |
CN102309589A (zh) | 一种左金胃漂浮片及其制备方法 | |
CN100506219C (zh) | 一种三七止血药的制备方法 | |
CN111544473A (zh) | 一种治疗冠心病心绞痛的精制冠心颗粒提取制备工艺、中药及其提取物 | |
CN1919242B (zh) | 治疗心脑血管疾病的中药组合物 | |
CN109303785A (zh) | 一种党参炔苷类似化合物在制备治疗心率失常药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIDA SHIJIA TECHNOLOGY DEVELOPMENT CO., LTD. Free format text: FORMER OWNER: ZHOU YAWEI Effective date: 20150119 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150119 Address after: 100084 No. 123 North Main Street, Haidian District, Beijing, Zhongguancun Patentee after: Beida Shijia Technology Development Co.,Ltd. Address before: 100084, Beijing, Zhongguancun, Haidian District North 123 Avenue, branch office incubator room 2206 Patentee before: Zhou Yawei |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 102206, 20 floor, No. 6, life road, Beijing, Changping District, 3 Patentee after: Beida Shijia Technology Development Co.,Ltd. Address before: 100084 No. 123 North Main Street, Haidian District, Beijing, Zhongguancun Patentee before: Beida Shijia Technology Development Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100127 |
|
CF01 | Termination of patent right due to non-payment of annual fee |